Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 275

Posts Tagged ‘almirall’

Almirall revalidates its excellence in occupational health and safety, environment and energy management

Posted by fidest press agency su giovedì, 4 luglio 2019

Almirall, S.A. (ALM) has achieved several important international accreditations after an external audit of its integrated corporate management system for occupational health and safety, environment and energy, developed by up to seven auditors from TÜV Rheinland, which carried out field inspections during twelve days at the company’s headquarters in Barcelona, its R&D Centre in Sant Feliu de Llobregat and its chemical and pharmaceutical plants in Sant Andreu de la Barca (Barcelona, Spain).
As a consequence of the audit results, the leading global pharmaceutical company has become one of the first in achieving two of the latest standardized international accreditations, both in its sector and in the whole business network: ISO 45001:2018, for occupational health and safety, and ISO 50001:2018, for energy management.
On the other hand, after obtaining the ISO 14001:2015 adaptation’s certificate in 2018, TÜV Rheinland’s auditors have revalidated the company’s environmental management effectivity. ISO 14001:2015 is the latest actualization of the standard ISO 140001, that Almirall reached in 2004 and is renewed periodically since then.
The process of continuous improvement is consubstantial to quality and excellence, so that the accreditations given by the International Organization for Standardization (ISO) collect a broad set of cross-cutting policies, processes and activities that must be implemented in its entirety as part of an integrated management system, and when all this set of initiatives is properly applied, it is possible to quantify significant improvements in a series of predetermined indicators.In the case of occupational health and safety management, Almirall has implemented an occupational risk prevention system that has allowed to achieve a low accident rate, significantly lower than the average for the pharmaceutical sector, both in Almirall headquarters and in its subsidiary Spanish centers. In addition, 16% of the hours of training that the company offers its employees are dedicated to the promotion of occupational health and safety, and wellbeing.On the other hand, the environmental management system has allowed the company to achieve a reduction in the emission of greenhouse gases by 38% between 2014 and 2018, considering the purchase of renewable energies; to reduce the waste by 7% in its chemical plants in 2018, and to reduce the use of methylene chloride by 61% since 2013.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for atopic dermatitis

Posted by fidest press agency su mercoledì, 26 giugno 2019

Almirall, S.A. (ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement in February 2019 pursuant to which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 MM. As a result of Almirall’s decision to exercise its option, the company will pay Dermira $50 MM and Dermira will be eligible to receive additional payments upon the achievement of certain milestones, including $30 million in connection with the initiation of certain Phase 3 clinical studies.Almirall’s decision follows positive topline results reported by Dermira in March 2019 from a Phase 2b dose-ranging study that showed all three doses of lebrikizumab met the primary endpoint, and demonstrated dose-dependent improvements across a range of measures characterizing the signs and symptoms of moderate-to-severe atopic dermatitis, including itch and skin inflammation, compared to placebo. The safety profile observed in the study was consistent with prior studies of lebrikizumab. The findings suggest that lebrikizumab has the potential to be a best-in-disease therapy for people living with moderate-to-severe atopic dermatitis. Following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, Dermira plans to initiate a Phase 3 clinical development program for lebrikizumab by the end of 2019.
Lebrikizumab is a novel, injectable, humanized monoclonal antibody designed to bind interleukin-13 (IL-13) with very high affinity, specifically preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening and infection.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall recognized as distinguished Corporate Leader by American Skin Association – Unveiled patient-proven purpose

Posted by fidest press agency su domenica, 14 aprile 2019

Almirall, S.A (ALM) was recognized this week with the Distinguished Corporate Leadership award by the American Skin Association (ASA).Ron Menezes, President and General Manager of Almirall, LLC received the award on behalf of the more than 1800 employees of the company from around the globe. He talked about Almirall’s corporate purpose of helping patients realize a healthy life, which aligns to the mission of the ASA. To illustrate this, he gave a moving presentation about a real acne patient whose successful treatment transformed their world.“This was a 16 years old male patient with severe acne who was hiding away from the world” mentioned Ron Menezes. “He wouldn’t meet the eyes of his dermatologist when he first visited him to get help. At his first follow up visit 4 weeks later he already had a significant improvement, but more importantly he had “come out of his shell” as his mother said. He was reaching out to friends again and was socializing, and she was relieved and happy to see that.” Concluding, Ron Menezes said “This demonstrates how by helping patients achieve treatment of their skin diseases we can transform their world for the better.”
The mission of the ASA is to advance research, champion skin health and drive public awareness about skin disease. Over the course of their 32 years history to date, the visionary leadership of the Association has supported the work of over 300 scientists and investigators by committing more than $50 MM to advance dermatological research. Their successful projects have included the establishment of a model research facility at Weill Cornell medical college and providing free instruction on sun protection and skin health through award-winning public-school programs.Dr. David Norris, University of Colorado and President of the board of directors for the ASA, who presented Ron Menezes with the Corporate Leadership award, highlighted Almirall’s contribution to the field of dermatology. “I’m impressed with Almirall’s spectrum of new treatments for important skin diseases, in some areas that we, as clinicians, haven’t had new treatments in for years. Through pharmacological innovation and strong commitment to global health care partnerships, Almirall is dedicated to providing the tools, knowledge and science to improve the health of patients worldwide”.The recognition of Almirall by the ASA is the latest achievement in the company’s goal of being recognized as a leader in medical dermatology in the US and globally.Peter Guenter, CEO of Almirall SA said “We are pleased to have received this award from such an esteemed organization. The ASA mission aligns with the new Almirall’s corporate purpose of transforming the patients’ world by helping them realize their hopes and dreams for a healthy life. We look forward to working with them, and the rest of the dermatology community, to make this purpose a reality”.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Treatment of patients with chronic obstructive pulmonary disease

Posted by fidest press agency su mercoledì, 3 aprile 2019

Almirall, S.A (ALM), announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Duaklirâ (aclidinium bromide/formoterol 400/12 mg, twice daily), for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Duaklir® offers a fixed-dose combination of a novel long-acting muscarinic antagonist (LAMA), aclidinium bromide and a fast long acting beta2-agonist (LABA), formoterol fumarate, administered through the GENUAIR® inhaler device.The FDA has approved Duaklir® based on the positive results of the AMPLIFY study, that shows Duaklir® significantly improved lung function in patients with moderate to severe COPD compared to each individual component (either aclidinium bromide or formoterol). The Phase III AMPLIFY study also proved that the efficacy, safety and tolerability profiles for aclidinium bromide and formoterol were consistent with current experience. In comparison to tiotropium bromide 18µg once-daily, both Duaklir® and aclidinium bromide monotherapy demonstrated significantly higher levels of bronchodilation during the night-time, whilst aclidinium bromide monotherapy showed non-inferior bronchodilation to tiotropium over 24 weeks. This approval by the FDA in the US means another positive step in the partnership of Almirall and AstraZeneca.In addition this is the third product discovered in the R&D Center of Almirall approved by the FDA.
The positive results of the Phase IV ASCENT trial for Tudorza® Pressair® (aclidinium bromide 400 μg, twice-daily) with 3.600 patients demonstrating a statistically significant reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo, has been translated in a relevant change in the Package Insert of this product in the US and also reflected in the current approval of Duaklir®.On 1st November 2014, Almirall entered an agreement to transfer the rights for the development and commercialisation of its respiratory franchise, as well as its pipeline of investigational novel therapies to AstraZeneca. This global collaboration included milestones associated to development, launch and future Duaklir® sales in US.Almirall could receive additional milestones and royalties, which have not been disclosed.Almirall remains positive about this partnership that has allowed to maximize the return and value of the company’s assets and capabilities.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall and HitGen will develop novel oral compounds in atopic dermatitis

Posted by fidest press agency su giovedì, 28 marzo 2019

Almirall, S.A. (ALM) announced the signature of a new research collaboration with HitGen Ltd. The company is conducting a multi-target research collaboration with DNA-Encoded library companies for targets in atopic dermatitis to develop novel oral chemical entities (NCE) for patients suffering from moderate to severe atopic dermatitis.In this sense, Almirall has entered into a collaboration with HitGen, a privately held biotechnology company established since 2012 in Chengdu, China, to establish an advanced lead generation platform based on their DNA-Encoded libraries for this specific target. HitGen has a robust platform with an extensive library (nearly 400 billion compounds) and a strong track record of deal making, which makes it an excellent partner for Almirall.The purpose of this strategic partnership is the identification of advanced hits, to be licensed by Almirall.
Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.
The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.
HitGen is a rapidly growing biotech company with headquarters and main research facilities based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug centred around the design, assembly and interrogation of DNA encoded chemical libraries (DELs). HitGen’s DELs contain nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthe-sised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and un-precedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and agrochemical solutions.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall announced that a key milestone under the collaboration with Nuevolution has been achieved

Posted by fidest press agency su lunedì, 4 marzo 2019

The strategic collaboration was entered on December 12, 2016 with the aim to develop innovative RORγt inhibitors with best-in-class potential for the oral and topical treatment of Dermatology diseases and Psoriatic Arthritis.A significant part of the collaboration work has been to evaluate preclinical safety parameters of RORγt inhibition and to comprehensively de-risk the program prior to any human testing. The milestone data achieved supports a program with a Candidate Drug (CD) having best-in-class potential.The program continues its progression towards clinical development. The positive result triggered a contractual milestone to Nuevolution.Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented “we are very pleased with the progress achieved in our strategic collaboration with Nuevolution, which reflects Almirall’s commitment to becoming a leader in medical dermatology by reinforcing our pipeline with true innovative best in class solutions”.Alex H. Gouliaev, Ph.D., Chief Executive Officer of Nuevolution, commented: “this underscores the positive opportunities for this very unique program. The program development has benefitted significantly from much synergy between and dedication by the teams”.Almirall had one of the highest levels of R&D investments in the Spanish Pharmaceutical Industry in 2018, representing over 12% of Net Sales (€88 MM). In addition, Almirall invests in assets, strategic partnerships and collaborations in research. For more information, please visit almirall.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

Posted by fidest press agency su giovedì, 14 febbraio 2019

Almirall, S.A. (ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that the companies have entered into an option and license agreement under which Almirall has acquired an option to exclusively license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. In exchange, Dermira will receive an upfront option fee of $30 MM. If Almirall exercises its option to obtain the license following the results of the ongoing Phase 2b study, Dermira will receive a $50 MM option exercise fee and will be eligible to receive additional development, regulatory and sales milestone payments, as well as double-digit royalties.
Under the terms of the agreement, Almirall will make an initial payment of $30 MM to Dermira in exchange for an option to acquire an exclusive license to develop lebrikizumab in dermatology indications and commercialize lebrikizumab in all indications in Europe. Following the availability of topline data from Dermira’s ongoing Phase 2b clinical study of lebrikizumab in moderate-to-severe atopic dermatitis, Dermira will provide to Almirall a data package consisting of topline and additional data, after which Almirall will have 45 days to exercise its option. If Almirall elects to exercise its option, the company will pay Dermira an option exercise fee of $50 MM.If Almirall exercises its option, Almirall will be obligated to make additional payments to Dermira upon the achievement of certain milestones, including $30 MM in connection with the initiation of certain Phase 3 clinical studies and up to $85 MM upon the achievement of regulatory milestones and the first commercial sale of lebrikizumab in Europe. In addition, Dermira will be entitled to receive milestone payments upon the achievement of certain thresholds for net sales of lebrikizumab in Europe, as well as royalty payments representing percentages of net sales that range from the low double-digits to the low twenties.“At Almirall, we continue to deepen in our commitment to dermatology,” said Peter Guenter, Chief Executive Officer of Almirall. “Atopic dermatitis is a condition that affects millions of people living in Europe, and we are pleased to support the development and commercialization of lebrikizumab, a differentiated treatment that we believe could become a best-in-disease therapy for these patients. We are excited to be collaborating with Dermira and look forward to positive results from the Phase 2b study and subsequently moving into registrational studies.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Francesca Domenech Wuttke, new Chief Digital Officer and new member of the Management Board in Almirall

Posted by fidest press agency su sabato, 5 gennaio 2019

Almirall, S.A. has announced the appointment of Francesca Domenech Wuttke as the new Chief Digital Officer and member of the Management Board of the company.
In her new role, Francesca Domenech Wuttke will report directly to Peter Guenter, Chief Executive Officer, Almirall, and will be responsible for developing and executing the end-to-end digital strategy, a key pillar in the future success of Almirall.She will lead the Digital Transformation for Almirall, defining the new digital governance model, developing and prioritizing the enterprise wide Digital Project Portfolio and working closely with all business stakeholders.“Digital transformation in healthcare is a huge opportunity for any biopharmaceutical company. We are certain that Francesca is the best person to lead the transformation with Almirall”, explained Peter Guenter, Chief Executive Officer, Almirall. “She will join us after more than 25 years of international strategic, commercial and transactional experience. She has excellent firsthand knowledge of the potential that digital technology has in the healthcare industry, so we are fortunate to have her”.During the last few years, Francesca has led European investments as Managing Director Europe for the Global Health Innovation Fund MSD’s venture capital arm. The fund is exclusively focused on investments in digital health solutions and services and there, she designed the investment thesis to accelerate the digital clinical trial ecosystem, with much success. For example, she invested in a digital clinical trial patient recruitment platform as well as a platform that interrogates electronic medical records for genomic phenotyping, clinical trial applications and Real World Evidence. Previously, she also worked as Global Director, Commercial Strategy at Novartis and she was co-founder of Asten BioPharma Avisors, a healthcare consultancy that supports business development of biopharmaceutical companies interested in investments in biotechnology. During her experience in venture capital, private equity, start-ups, consulting and pharma companies, Francesca has shown a great ability to distill scientific and clinical data into investment opportunities, having prospected and evaluated hundreds of opportunities.Francesca holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a B.A. in Biology and Society by the Cornell University College of Arts and Sciences. Francesca is an American citizen who lives with her family in Barcelona.

Posted in Economia/Economy/finance/business/technology, Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Almirall builds the largest self-consumption photovoltaic plant in Catalonia

Posted by fidest press agency su mercoledì, 28 novembre 2018

Almirall, S.A (ALM) has completed the construction of an innovative 800 kWp photovoltaic plant, located in its pharmaceutical plant in Sant Andreu de la Barca (Barcelona), which aims to save 12% of the electrical energy consumption from the site. This initiative is part of the company’s policy to reduce carbon dioxide emissions by promoting the use of renewable energies.The installation of this solar facility, which is the result of Almirall’s efforts to create an energy efficiency model through innovative projects, represents an important precedent in the fight against climate change. Already in 2017, Almirall installed the first solar panel system in Spain connected directly to its chemical plant in Sant Celoni (Barcelona)
With the construction of this photovoltaic plant, Almirall expects to reduce its dependence on the electrical network by more than 1,200 MWh per year in its Sant Andreu plant. It will generate the equivalent to the average annual consumption of approximately 350 homes with 100% renewable and local energy. Furthermore, the construction of the photovoltaic facility will reduce emissions by 479 tons of CO2 into the atmosphere.All the energy to be produced by this photovoltaic installation will be instantaneously consumed by the Sant Andreu plant, covering 12% of its electrical needs.The solar panels will be installed on the roof of the building, the canopies of the parking lot and on the ground, and the photovoltaic plant will transform the solar radiation into electrical energy.This technology is able to capture the maximum energy during all hours of the day and all months of the year. The power output is 800 kWp, allowing to generate close to 1,200 MWh per year of clean energy for self-consumption.With the opening of the Sant Andreu de la Barca solar plant, Almirall reinforces its strategy of implementing ongoing measures to make its production processes more sustainable and to reduce the environmental impact in all the company’s operational areas. The efforts in this area extend throughout all the life cycle of the product: from its R&D and manufacture, to the acquisition of raw materials and the waste disposal process.Since 2012, Almirall has managed to reduce its energy consumption of electricity and gas by 18% by implementing 149 energy efficiency projects, with the common objective of reducing the effects of climate change.” Our main purpose is to promote renewable energy in all sites. We take care of people, that is why we are committed to finding energy efficiency solutions, to contribute to the construction of a more sustainable environment “, stated Victor Molina.Almirall’s energy efficiency model is based on the iterative search for projects and new technologies that have been applied progressively, according to the needs of each site. In this way, the company has managed to implement innovative technologies such as magnetic levitation and humidification by water nebulization by high compression, which allow the reduction of energy consumption in compressors of refrigeration equipment and steam systems by resistances and/or traditional electrolysis.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall and the Barcelona Supercomputing Center to collaborate in SilicoDerm project

Posted by fidest press agency su domenica, 4 novembre 2018

SilicoDerm is a research project aimed to develop novel computational drug design methodologies applied to dermatological targetsThe application of SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases, specifically atopic dermatitis and psoriasis. Almirall, S.A. and the Electronic and Atomic Protein Modeling Group (EAPM) from the Life Sciences Department of the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) have entered into a research collaboration, SilicoDerm, a project focused on computational drug design applied to dermatological therapeutic targets.SilicoDerm aims to develop novel high-performance computational methodologies that facilitate the identification of active compounds for the treatment of inflammatory skin diseases of Almirall’s interest, such as psoriasis and atopic dermatitis. The project scope encompasses from the development of the computational methodologies for two novel therapeutics targets, to the synthesis and evaluation of the compounds identified in-silico. The new protein-based 3D virtual screening methodologies of SilicoDerm will allow to study thousands of compounds in a faster and a more reliable way than current computational methodologies.Dr. Jordi Gràcia, Head of Drug Discovery, Almirall, commented: “Our collaboration with BSC is an outstanding opportunity for Almirall R&D. The application of these novel computational methodologies for drug design will facilitate the identification of new compounds, and therefore, reduce the time of development of new drugs that will broaden our spectrum of potential treatments for unmet medical needs in patients with skin diseases.”At the same time, Dr. Víctor Guallar, leader of the Electronic and Atomic Protein Modelling Group from the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS), stated: “This project shows the maturity of the modeling techniques developed at BSC to address real life drug design projects. We invested many years of research to get here.”
This project is being financed by the Ministry of Science, Innovation and Universities (MICINN) through the grants Reto de Colaboración 2017 and co-financed by FEDER funds from the European Commission.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Almirall and Evotec enter into research collaboration in the field of dermatological diseases

Posted by fidest press agency su martedì, 18 settembre 2018

Almirall, S.A. (Spanish Stock Exchange. ticker: ALM) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced that they have entered into a research collaboration with to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties.Dr. Bhushan Hardas, Executive Vice President R&D, Chief Scientific Officer of Almirall, said: “Our R&D strategy focuses towards achieving innovative and breakthrough products to cover patients’ unmet needs. This partnership with Evotec, an expert in delivering fast growing and profitable drug discovery and development business, represents a step forward in offering outstanding solutions for the treatment of dermatology diseases with the best technology available and with substantial benefit to patients suffering from dermatological disorders.”Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said: “Evotec is pleased to partner with Almirall in the field of dermatology, who is a globally recognised leader in the field. The goal is to jointly address highly validated targets via a new approach that has the potential to deliver superior first-in-class drug products. This platform enables disruption of cell signaling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Almirall appoints Peter Guenter as new CEO

Posted by fidest press agency su giovedì, 31 agosto 2017

Peter GuenterBarcelona. Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the Board of Directors has approved the appointment of Mr. Peter Guenter as CEO of Almirall effective October 1st, 2017. Peter Guenter joins us from Sanofi, where he has worked for the last 22 years, most recently as Executive Vice President Diabetes and Cardiovascular Global Business Unit. During his tenure at Sanofi, he held many senior positions including Vice President Eastern Europe and Northern Europe, Vice President Business Management and Support, General Manager Germany, Senior Vice President Europe, Executive Vice President Global Commercial Operations and Executive Vice President General Medicine and Emerging Markets. Before joining Sanofi, he held different positions in sales and marketing at Smith Kline and Ciba Geigy.“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level”, said Jorge Gallardo, Chairman of the Board of Almirall.“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the center of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall”, said Peter Guenter.
Peter Guenter is Belgian and holds a Master’s Degree in Physical Education from the Faculty of Medicine and Health Sciences, University of Ghent. Eduardo Sanchiz has been in Almirall for thirteen years and was appointed CEO in July 2011. We very much appreciate his efforts and contribution to the company, particularly for his leadership in the strategic transformation process. We wish him all the best in the future.Eduardo and Peter will transition during the month of September.Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programmes including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.
Founded in 1943, with headquarters in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the long-standing commitment of its major shareholders. In 2016, its revenues totalled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US. (photo: Peter Guenter)

Posted in Recensioni/Reviews | Contrassegnato da tag: , | Leave a Comment »

Trattamento dei pazienti con psoriasi cronica a placche

Posted by fidest press agency su venerdì, 14 luglio 2017

psoriasiLa Commissione Europea ha approvato un nuovo prodotto orale a base di dimetilfumarato (DMF) per il trattamento dei pazienti con psoriasi cronica a placche da moderata a grave. E’ indicato come trattamento di induzione e a lungo termine. Almirall commercializzerà il farmaco nel terzo quadrimestre del 2017 in tutti gli Stati dell’Unione Europea, in Islanda e in Norvegia. “La psoriasi è una patologia cronica e recidivante della pelle che colpisce circa 1,5 milioni di persone in Italia – ha affermato il prof. Giuseppe Micali, Direttore della Clinica Dermatologica, Università di Catania P.O. ‘G. Rodolico’, Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele di Catania -. La qualità di vita dei pazienti affetti è fortemente compromessa a causa delle manifestazioni cliniche caratterizzate da desquamazione, prurito, secchezza e bruciore a livello delle zone del corpo interessate. Attualmente la psoriasi va considerata una patologia infiammatoria multisistemica, potendo coinvolgere più organi. Quanto più vaste infatti sono le parti di pelle interessate e quanti più sono gli anni di convivenza con le lesioni, tanto maggiore è il rischio di avere un’altra malattia o comorbidità, come artrite psoriasica, obesità, ipertensione, diabete e dislipidemie. La psoriasi inoltre ha un elevato impatto sulla qualità di vita dei pazienti intaccando la loro autostima, determinando talora l’insorgenza di disturbi depressivi, ed influendo negativamente sulle relazioni sociali e interpersonali”. “Dimetilfumarato è un estere dell’acido fumarico che esplica la sua attività bloccando la produzione di citochine proinfiammatorie; si è dimostrato efficace nel trattamento, anche a lungo termine, della psoriasi a placche moderata-grave – ha sottolineato il prof. Giampiero Girolomoni, Direttore dell’Unità Operativa di Clinica Dermatologica all’Ospedale Borgo Trento di Verona -. “L’approvazione della Commissione europea è un’ottima notizia per i professionisti della salute e per gran parte dei pazienti europei che potranno accedere a una nuova opzione terapeutica per il trattamento sistemico della psoriasi da moderata a grave – ha commentato Eduardo Sanchiz, CEO di Almirall -. DMF è il risultato dell’impegno di Almirall nell’innovazione e la sua disponibilità per i medici e i pazienti colpiti da psoriasi rappresenterà un importante passo in avanti nel rinforzare la posizione dell’azienda come significativo partner nel settore della dermatologia”.
La prima presentazione dei risultati è avvenuta a settembre 2016 al 25° Congresso della European Academy of Dermatology and Venereology di Vienna (Austria).
Pubblicato sul British Journal of Dermatology, lo studio BRIDGE ha dimostrato la non-inferiorità di DMF vs esteri dell’acido fumarico, e il suo buon profilo di efficacia e sicurezza1. Ad oggi la combinazione di esteri dell’acido fumarico era disponibile solo in Germania in una diversa composizione così come in formulazioni prodotte localmente in Olanda, Austria e in alcuni Stati del Nord Europa. La decisione della Commissione Europea renderà disponibile questa nuova formulazione orale per tutti i pazienti europei.
Gli esteri dell’acido fumarico costituiscono un trattamento sistemico consolidato per la psoriasi e sono raccomandati dalle linee guida europee sia per l’induzione che per il trattamento a lungo termine. Le evidenze a lungo termine che derivano da studi e da dati di registro retrospettivi mettono in evidenza l’utilità clinica del farmaco.

Posted in Medicina/Medicine/Health/Science, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Al via la collaborazione fra Almirall e Nercachem per lo sviluppo di bloccanti delle citochine

Posted by fidest press agency su venerdì, 23 dicembre 2016

barcellonaBarcellona. Almirall e Mercachem hanno siglato un accordo di collaborazione esclusivo per lo sviluppo di bloccanti orali delle citochine per il trattamento delle malattie infiammatorie della pelle. In base ai termini dell’accordo, Mercachem condurrà campagne per identificare i bloccanti orali delle citochine e permetterne l’ulteriore sviluppo da parte di Almirall. Almirall sarà responsabile del finanziamento dell’attività di ricerca di Mercachem in quest’area e realizzerà qualsiasi attività futura in campo preclinico, clinico, regolatorio e commerciale. Mercachem riceverà un pagamento upfront di 1 milione di euro, rimborsi spese per la ricerca e potrà ricevere altri pagamenti al raggiungimento di obiettivi di sviluppo fino a un massimo di 5,5 milioni di euro. “Siamo orgogliosi di iniziare questa collaborazione di ricerca con Mercachem – ha affermato Thomas Eichholtz, CSO di Almirall -, perché ci permette di accedere a tecnologie all’avanguardia per identificare piccole molecole in grado di bloccare le interazioni proteina-proteina. Tutto questo apre la via a un’intera nuova categoria di bersagli per farmaci di grande interesse per la nostra area terapeutica, la dermatologia. E questa collaborazione è un ulteriore esempio della nostra strategia innovativa”. “Siamo felici di condividere uno dei nostri progetti innovativi con Almirall – ha commentato Gerhard Müller, Senior Vice President Medicinal Chemistry di Mercachem – volti alla ricerca e ottimizzazione di un target veramente stimolante”. “In una precedente collaborazione con Vipergen – ha aggiunto – abbiamo dimostrato che il dosaggio DNA-encoded library che utilizza la tecnologia BTE di Vipergen ha dato ottimi risultati di grande utilità nella chimica medica per colpire difficili bersagli cellulari.”
Mercachem è un’organizzazione privata leader in Europa per la ricerca a contratto che offre servizi innovativi di ricerca nel campo della chimica, chimica medica e nella ricerca iniziale e produzione GMP per accelerare la scoperta di nuovi farmaci e il loro processo di sviluppo in modo flessibile e costo-efficace. La collaborazione con molte Aziende farmaceutiche e biotech in tutto il mondo ha permesso a Mercachem di essere riconosciuta per i suoi prodotti e servizi di alta qualità e le sue capacità di ‘problem solving’ senza precedenti.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Almirall e Nuevolution siglano una collaborazione strategica per lo sviluppo di inibitori RORyt

Posted by fidest press agency su martedì, 20 dicembre 2016

barcellonaBarcellona, Almirall e Nuevolution hanno siglato una collaborazione strategica globale focalizzata allo sviluppo e alla commercializzazione di un programma riguardante un nuovo agonista inverso (inibitore) di RORyt di Nuevolution per il trattamento di malattie infiammatorie cutanee e altri disordini come l’artrite psoriasica. Come parte dell’accordo, le due aziende stabiliranno una collaborazione di ricerca per l’identificazione di altri inibitori di RORyt, con un’opzione esclusiva per Almirall di utilizzarli in ambito dermatologico e un uso opzionale al di fuori del campo di collaborazione per Nuevolution. Almirall sarà responsabile del finanziamento di qualsiasi ulteriore attività di ricerca, oltre all’attività preclinica, clinica, regolatoria e commerciale. Nuevolution sarà responsabile del finanziamento della propria ricerca. Nuevolution riceverà un pagamento upfront di 11,2 milioni di euro (109,4 milioni di SEK*) e potrà ricevere altri pagamenti al raggiungimento di obiettivi di sviluppo e regolatori fino a un totale massimo di 172 milioni di euro (1,7 miliardi di SEK*), sulla base del successo dello sviluppo, e al raggiungimento di obiettivi di vendite commerciali fino a un totale massimo di 270 milioni di euro (2,6 miliardi di SEK*). Nuevolution avrà diritto a ricevere diritti sulla base delle vendite nette future. “Siamo galvanizzati da questa collaborazione con Almirall – ha affermato Alex Haahr Gouliaev, CEO di Nuevolution -. Almirall è un’azienda farmaceutica leader mondiale nel settore del trattamento di malattie dermatologiche e, attraverso la collaborazione con Almirall, il nostro programma ha trovato un forte partner per proseguire nello sviluppo e nella successiva commercializzazione. Ci aspettiamo un’eccellente collaborazione con Almirall”. “Questo accordo con Nuevolution – ha commentato Eduardo Sanchiz, CEO di Almirall – ci permetterà di sviluppare inibitori di RORyt per il trattamento di malattie dermatologiche e dell’artrite psoriasica. Questo programma include nuovi prodotti chimici che promettono di essere tra i primi di una nuova classe di anti-infiammatori non steroidei orali. Siamo fieri di aver intrapreso questa collaborazione strategica con Nuevolution, che rinforza la nostra pipeline e porta con sé un’ulteriore potenziale spinta nella crescita di Almirall, mentre continuiamo a posizionarci come azienda leader in dermatologia. La collaborazione mostra anche il nostro continuo impegno di portare avanti l’innovazione dalle fonti migliori.” “Focalizziamo il nostro talento, la nostra energia e il nostro impegno per migliorare la qualità di vita dei pazienti con problemi dermatologici ed estetici, grazie al valore e all’innovazione dei trattamenti che sviluppiamo, produciamo e distribuiamo -, ha spiegato Alessandro Lattuada, Country Manager Almirall, Italia -. L’accordo di collaborazione con Nuevolution è un altro importante passo avanti nello sviluppo di nuove soluzioni per soddisfare le esigenze dei pazienti e, in questo modo, ci aiuterà a realizzare la nostra missione.”
Nuevolution AB (publ) è un azienda leader biotech di piccole molecole fondata nel 2001, con sede a Copenhagen (Danimarca). Ha siglato collaborazioni per la sua piattaforma proprietaria di ricerca e programmi con aziende farmaceutiche e biotecnologiche per cercare benefici futuri per i pazienti che necessitano di nuove opzioni di trattamento. I programmi interni di Nuevolution sono focalizzati su importanti target terapeutici nell’infiammazione, oncologia e immuno-oncologia.
Questa informazione è sottoposta all’obbligo di Nuevolution AB (publ) di rendere pubblica la sua condizione secondo l’EU Market Abuse Regulation and the Securities Market Act. L’informazione è stata resa pubblica, attraverso i contatti sottoindicati lunedì 12 dicembre alle ore 11:00. Nuevolution AB (publ) è quotata al Nasdaq First North Premier di Stoccolma, Svezia (ticker: NUE.ST). Redeye AB agisce come Certified Adviser per Nuevolution AB (publ).

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Almirall and Sun Pharma enter into a License Agreement for Tildrakizumab in Europe for Psoriasis

Posted by fidest press agency su venerdì, 29 luglio 2016

psoriasiMumbai, India and Barcelona, Spain July 27, 2016 – Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies), and its wholly owned subsidiary and Almirall (Spanish Stock Exchange ticker: ALM) today announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being evaluated in patients with moderate-to-severe plaque psoriasis.Under terms of the license agreement, Almirall will pay Sun Pharma an initial upfront payment of US $50 million. Phase-3 studies of tildrakizumab have recently been completed. Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales, the terms of which are confidential. Almirall will be able to lead European studies, and participate in larger Global clinical studies for psoriasis indication subject to the terms of the Sun Pharma – Merck agreements, as well as certain cost sharing agreements. Sun Pharma will continue to lead development of tildrakizumab for other indications, where Almirall will have right of first negotiation for certain indications in Europe.“Sun Pharma is committed to growing our dermatology franchise, with tildrakizumab as our lead investigational compound. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are proud to be partnering with a regional leader in dermatology, like Almirall, to bring tildrakizumab to the European market,” said Dilip Shanghvi, Managing Director, Sun Pharma. “This agreement with Almirall follows the recent announcement that tildrakizumab is the first IL-23p19 inhibitor to demonstrate positive results in Phase-3 clinical trials and is another step towards preparing for future regulatory milestones that will potentially enable us to bring a new treatment option to patients with moderate-to-severe plaque psoriasis.”“This agreement with Sun Pharma allows us to add a novel biologic for treatment of psoriasis to our extensive dermatology portfolio,” said Jorge Gallardo, President of Almirall. “This is an exciting time for the treatment of psoriasis, a disease which can take both a physical and emotional toll on patients’ lives. Emerging new investigational drugs, like tildrakizumab, are increasingly targeted and will potentially offer patients and physicians another alternative.”Additionally, the license agreement has a provision for possible co-promotion agreement at some point in the future, subject to certain conditions.
In May 2016, the two pivotal Phase-3 clinical trials of tildrakizumab met their primary endpoints for both evaluated doses with topline results shared via a separate press release. The co-primary efficacy endpoints were: the proportion of participants with Psoriasis Area Sensitivity Index 75 (PASI 75) response at week 12 compared to placebo and the proportion of participants with a Physician’s Global Assessment (PGA) score of clear or minimal with at least a 2 grade reduction from baseline at week 12 compared to placebo. The overall safety profile of tildrakizumab in both Phase-3 clinical trials was consistent with the safety data observed in previously reported studies. Additionally, the second study included an etanercept comparator arm, with a key secondary endpoint comparing tildrakizumab and etanercept on PASI 75 and PGA. Tildrakizumab 200mg was superior to etanercept on both PASI 75 and PGA endpoints at week 12, while the 100 mg dose showed superiority to etanercept on PASI 75 only.The preparations for submission of a Biologics License Application to the U.S. Food and Drug Administration are proceeding. The detailed findings from the Phase-3 clinical trials will be presented at upcoming scientific meetings.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

L’esperienza di Almirall nello sviluppo di prodotti terapeutici

Posted by fidest press agency su venerdì, 27 maggio 2016

biotecnologiaAlmirall e Bicosome, start-up che sviluppa e commercializza cosmetici e prodotti dermo-farmaceutici a elevata performance, hanno annunciato l’avvio di un accordo di ricerca, collaborazione e sublicenza per lo sviluppo di diversi prodotti dermatologici topici, basati su Bicosome® Technology, piattaforma di sviluppo tecnologico. Secondo i termini dell’accordo, Bicosome sarà responsabile delle attività di ricerca per sviluppare modelli preclinici utilizzando il sistema brevettato di incapsulazione e Almirall provvederà allo sviluppo clinico, alle procedure regolatorie, alle attività di produzione e commercializzazione del prodotto sviluppato.
Bicosome® Technology è una piattaforma tecnologica innovativa per il rilascio cutaneo in grado di trasportare e far arrivare in modo selettivo principi attivi al loro sito d’azione. Questa tecnologia è stata creata per risolvere le limitazioni di penetrazione cutanea dei principi attivi, una delle maggiori sfide per i produttori di formulazioni per la cura della pelle. Gli ingredienti di Bicosome® sono in grado di proteggere le molecole dalla degradazione, di modulare la funzione barriera della cute senza danneggiarla e di penetrare e arricchire lo strato cutaneo, proprio dove i principi attivi devono essere rilasciati. Alessandro Lattuada, Coutry Manager Almirall S.p.A., ha affermato: “Questa collaborazione è un altro esempio dell’impegno di Almirall per sviluppare prodotti innovativi e rispondere ai bisogni insoddisfatti dei pazienti in campo dermatologico. Perché crediamo fermamente che se vince il paziente, allora vinciamo tutti. Questa collaborazione ci aiuterà a realizzare la nostra ambizione di diventare un’azienda farmaceutica specialistica leader con un forte focus per migliorare la qualità di vita dei pazienti in area dermatologica, massimizzando i risultati dei prodotti della nostra ricerca e sviluppo” . Con questo accordo, Almirall fa propria una tecnologia unica e differenziata, già utilizzata e validata nel mercato della cosmesi, per trasportare e rilasciare principi attivi al sito d’azione nella pelle. I prodotti basati su questa tecnologia offrono vantaggi nel migliorare l’aderenza del paziente, la stabilità e l’interazione dei principi attivi con la cute.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Almirall and Bicosome enter into a collaboration and sublicense agreement for the development of topical drug delivery formulations

Posted by fidest press agency su sabato, 21 maggio 2016

barcellonaBarcelona. Almirall S.A., the global pharmaceutical company based in Barcelona, and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, announced that they have entered into a research, collaboration and sublicense agreement for the development of multiple topical dermatological products, based upon Bicosome’s proprietary patented delivery technology platform, Bicosome® Technology.In accordance with the terms of the agreement, Bicosome will be responsible for the research activities to deliver preclinical product prototypes using their proprietary encapsulating system and Almirall will perform the clinical development, regulatory filings, manufacturing and commercialization activities of the developed products.Under the collaboration agreement, Bicosome grants Almirall a sublicense to develop and commercialize products in certain dermatological indications. Bicosome will receive research payments and is entitled to potential development milestone payments as well as tiered royalties on future Net Sales and sales milestones.Bicosome® Technology is an innovative technological platform for skin delivery able to transport and deliver actives selectively to their site of action. This technology was created to solve skin penetration limitations, one of the biggest challenges for skin care formulators. Bicosome® based ingredients are able to protect molecules from degradation, to modulate skin barrier function without damaging the skin, and to penetrate and reach the desired layer of the skin, where the active ingredients need to be delivered.
Through this agreement, Almirall incorporates a unique and differentiated technology, already used and validated in the cosmetic market, to transport and deliver actives to the site of action in the skin. Products based on this technology offer advantages in improving patient compliance, stability of the active agents and the interaction of the actives with the skin.Thomas Eichholtz, Chief Scientific Officer, and Executive Vice-President of R&D at Almirall, commented: “We are delighted to enter into this collaboration with Bicosome, which once again demonstrates our desire to become a global leader in Dermatology and gives us access to a potentially breakthrough technology in topical drug delivery. Our aim is to leverage cutting-edge technologies to cover unmet patient needs in Dermatology through targeted innovation in R&D and this partnership is a good sign of this commitment.”
Lucyanna Barbosa CEO at Biocosome addressed: “We are sure that we encountered in the collaboration with Almirall the adequate partner to validate our technology in dermopharmaceutical field. Bicosome® platform provides multiple benefits in the treatment of the skin, boosting both efficacy and safety of products. We look forward for the success of the project to benefit patients with our new concept for delivering medicines into the skin.” This collaboration is another example of Almirall’s commitment to developing innovative products to cover unmet needs in dermatological diseases.
Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of taking our innovative products wherever they are needed. Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2015, its revenues totalled 769 million euros and, with 1.800 employees, it has gradually built up a trusted presence across Europe, as well as in the USA. http://www.almirall.com.
Bicosome is a spin off company from the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) founded in 2012 and devoted to the development and manufacturing of high performance cosmetic and dermopharmaceutical ingredients using its proprietary patented technological platform: Bicosome® technology.
Bicosome core activity is the development of high performance ingredients from lab to industrial scale and their commercialization and licensing in a B2B fashion to Cosmetic and Pharmaceutical companies either directly or through a network of distributors. Bicosome has a proprietary line of cosmetic ingredients and develops as well tailored made ingredients with Cosmetic and Pharmaceutical indications.

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Almirall closes the acquisition of ThermiGen LLC entering the aesthetics market

Posted by fidest press agency su mercoledì, 10 febbraio 2016

barcellonaBarcelona. Almirall, S.A., the global pharmaceutical company based in Barcelona, today announced the completion of the acquisition of 100% of the share capital of ThermiGen LLC, after all closing conditions have been satisfied. In accordance with the terms of the agreement signed in September 2015, the transaction has been fulfilled and Almirall now owns this medical aesthetics company, which is a leading developer of thermistor-regulated energy systems for Aesthetics Dermatology and Plastic Surgery applications.
Under the terms of the agreement, Almirall has acquired ThermiGen for an Enterprise Value of $82 million This acquisition represents the definitive entry of Almirall into the aesthetics market, an industry with potential global sales in high growth dermatological indications. The addition of ThermiGen’s portfolio provides Almirall with a solid technology and commercial platform in the energy-based devices segment; a recurrent business model and an experienced management team with a proven track record. In 2014, ThermiGen had $11.4 million of revenue and has already closed 2015 with nearly $30 million in sales and positive operating results.Almirall announced the exercise of a call option on January 4th 2016. Previously, in September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company, now completed.This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are “forward-looking statements”. These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company’s control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading dermatology player. Our size enables us to be agile and flexible so that we can accomplish the purpose of taking our innovative products wherever they are needed.
Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2014, its revenues totaled 1,407 million euros and, with more than 2,100 employees, it has gradually built up a trusted presence across Europe, as well as in the US and Mexico.
The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.

Posted in Estero/world news, Medicina/Medicine/Health/Science, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Almirall exercises call option to acquire 100% of ThermiGen LLC

Posted by fidest press agency su lunedì, 4 gennaio 2016

barcelonaAlmirall, S.A., the global pharmaceutical company based in Barcelona, has announced the exercise of a call option to acquire 100% of the share capital of ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. In September 2015, Almirall acquired a minority stake in ThermiGen for USD $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of C. $80m. In accordance with the terms of the agreement, the transaction will be fulfilled during the month of January 2016.
ThermiGen’s product portfolio is based on thermistor-regulated energy systems applying what is becoming known as the ‘Science of Heat’, enabling physicians to use temperature as an endpoint to treat a variety of aesthetic soft tissue and nerve conditions. This technology is used for multiple non-invasive and minimally-invasive procedures, and it offers significant potential for multiple indications. ThermiRF®, the company’s flagship product, is the first FDA’s cleared aesthetic device that employs temperature-controlled radio frequency to be used in dermatological and general surgical procedures for electrocoagulation and hemostasis and to create lesions in nervous tissue. ThermiGen also has the worldwide rights to commercialize the Thermi250® which also employs temperature-controlled radio frequency using a specially designed thermistor regulated hand piece, which delivers precise heating to the skin’s surface.
ThermiGen, doing business as Thermi, is focused on the worldwide distribution of its products. In 2014, the company had $11.4m of revenue and is expecting to close 2015 with nearly $30m in sales and positive operating results. The company was founded in June 2012 by Paul Herchman (CEO) and Kevin O’Brien (President). Its Clinical Advisory Board is chaired by Plastic Surgeon Brian Kinney, MD and the company is based in Dallas (TX).This acquisition is in line with Almirall’s strategy to build presence in the dermatology aesthetics market, following a previous minority equity investment in Suneva Medical announced on July 29th 2015. Upon completion of the acquisition, the addition of ThermiGen’s portfolio provides Almirall with a technology and commercial platform in the energy-based devices segment; a recurrent business model and an experienced management team with a proven track record.
Jorge Gallardo, President of Almirall, commented: “This potential acquisition is the first step towards building a leading presence in the aesthetics market and it continues to consolidate our company as a leading Dermatology player. The structure of this two step deal has allowed Almirall to learn more about the market and about the company. We are confident that it represents an attractive opportunity to enter an exciting market with a potential global sales in high growth dermatological indications”.
“Because Thermi technology delivers effective and predictable outcomes, we have experienced impressive growth and fully expect this trend to continue for many years to come,” said Kevin O’Brien, Co-founder and President of Thermi. “The tireless work by our dedicated employee’s, brilliant physician clinical advisory council members, along with our unique technology solutions have all contributed to the rapidly growing demand for our technology solutions worldwide. The previous investment by Almirall and now this potential transaction gives Thermi the necessary resources to continue to execute its worldwide strategy,” said Paul Herchman, Co-founder and CEO of Thermi.

Posted in Economia/Economy/finance/business/technology, Estero/world news | Contrassegnato da tag: , | Leave a Comment »